Potency Labeling of Novel Factor VIII and Factor IX Concentrates: Past Experience and Current Strategy

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 8, 2015, Pages 849-854

  Hubbard, Anthony R ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

coagulation; factor IX; factor VIII; hemophilia

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; RECOMBINANT FACTOR VIII SQ;

ARTICLE; DRUG LABELING; DRUG PACKAGING; DRUG POTENCY; HEALTH; IN VITRO STUDY; IN VIVO STUDY; INTERNATIONAL STANDARD UNIT; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; BLOOD CLOTTING TEST; GENETICS; HEMOPHILIA A; HUMAN; METABOLISM; PROCEDURES;

BLOOD COAGULATION TESTS; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HUMANS;

EID: 84946720651     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1395353     Document Type: Article

References (49)

1. Peyvandi F.; Garagiola I.; Seregni S. Future of coagulation factor replacement therapy. J Thromb Haemost: 2013; 11 01 84 98
2. Shapiro A. D. Long-lasting recombinant factor VIII proteins for hemophilia A. Hematology (Am Soc Hematol Educ Program): 2013; 2013 37 43
3. Schaub R. G. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia. Biochem Pharmacol: 2011; 82 2 91 98
4. Oldenburg J.; Albert T. Novel products for haemostasis - current status. Haemophilia: 2014; 20 04 23 28
5. Gu J. M.; Ramsey P.; Evans V.; et al. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A. Haemophilia: 2014; 20 4 593 600
6. Barrowcliffe T. W.; Hubbard A. R.; Kitchen S. Standards and monitoring treatment. Haemophilia: 2012; 18 04 61 65
7. Hubbard A. R. International biological standards for coagulation factors and inhibitors. Semin Thromb Hemost: 2007; 33 3 283 289
8. Assay of human coagulation factor VIII (2.7.4) In: European Pharmacopoeia. 8th ed. Strasbourg, France Council of Europe: 2014; 8.0 236
9. Langdell R. D.; Wagner R. H.; Brinkhous K. M. Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure. J Lab Clin Med: 1953; 41 4 637 647
10. Proctor R. R.; Rapaport S. I. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol: 1961; 36 212 219
11. Seghatchian M. J.; Miller-Andersson M. A colorimetric evaluation of factor VIII: C potency. Med Lab Sci: 1978; 35 4 347 354
12. Rosén S. Assay of factor VIII: C with a chromogenic substrate. Scand J Haematol Suppl: 1984; 40 139 145
13. Barrowcliffe T. W. Standardization of FVIII & FIX assays. Haemophilia: 2003; 9 4 397 402
14. Hubbard A. R.; Weller L. J.; Bevan S. A. Activation profiles of factor VIII in concentrates reflect one-stage/chromogenic potency discrepancies. Br J Haematol: 2002; 117 4 957 960
15. Viuff D.; Barrowcliffe T.; Saugstrup T.; Ezban M.; Lillicrap D. International comparative field study of N8 evaluating factor VIII assay performance. Haemophilia: 2011; 17 4 695 702
16. Mikaelsson M.; Oswaldsson U.; Sandberg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia: 1998; 4 4 646 650
17. Ingerslev J.; Jankowski M. A.; Weston S. B.; Charles L. A.; ReFacto Field Study Participants. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII: C activity in hemophilic plasma using one-stage clotting assays. J Thromb Haemost: 2004; 2 4 623 628
18. Barrowcliffe T. W.; Mertens K.; Preston F. E.; Ingerslev J. Laboratory aspects of haemophilia therapy. Haemophilia: 2002; 8 3 244 249
19. Finney D. J. Statistical method in biological assay. 3rd ed. London Charles Griffin & Company Ltd.: 1978
20. Assay of human coagulation factor IX (2.7.11) In: European Pharmacopoeia 8th ed. Strasbourg, France Council of Europe: 2014; 8.0 248
21. Shapiro A. D.; Ragni M. V.; Valentino L. A.; et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood: 2012; 119 3 666 672
22. Metzner H. J.; Weimer T.; Kronthaler U.; Lang W.; Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost: 2009; 102 4 634 644
23. Ostergaard H.; Bjelke J. R.; Hansen L.; et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood: 2011; 118 8 2333 2341
24. Gray E.; Pickering W.; Hockley J.; et al. Collaborative study for the establishment of replacement batches for human coagulation factor IX concentrate reference standards. Pharmeur Bio: 2008; 2008 1 19 30
25. Bangham D. R.; Brozović M. Factor VIII international units and reference materials. Thromb Diath Haemorrh: 1974; 31 1 3 11
26. Hubbard A. R.; Weller L. J.; Bevan S. A. A survey of one-stage and chromogenic potencies in therapeutic factor VIII concentrates. Br J Haematol: 2002; 117 1 247 248
27. Raut S.; Daniels S.; Heath A. B.; SSC Sub-Committee on Factor. Value assignment of the WHO 8th International Standard for factor VIII, concentrate (07/350). J Thromb Haemost: 2012; 10 6 1175 1176
28. Lusher J. M.; Hillman-Wiseman C.; Hurst D. In vivo recovery with products of very high purity-assay discrepancies. Haemophilia: 1998; 4 4 641 645
29. Mikaelsson M.; Oswaldsson U. Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products. Semin Thromb Hemost: 2002; 28 3 257 264
30. Hubbard A. R.; Bevan S. A.; Weller L. J. Potency estimation of recombinant factor VIII: effect of assay method and standard. Br J Haematol: 2001; 113 2 533 536
31. Barrowcliffe T. W. Clotting factor concentrates in clinical practice. Standardization and assay. Semin Thromb Hemost: 1993; 19 1 73 79
32. Barrowcliffe T. W.; Raut S.; Hubbard A. R. Discrepancies in potency assessment of recombinant FVIII concentrates. Haemophilia: 1998; 4 4 634 640
33. Barrowcliffe T. W. Factor VIII and factor IX Sub-Committee. Recommendations for the assay of high-purity factor VIII concentrates. Thromb Haemost: 1993; 70 5 876 877
34. Raut S.; Sands D.; Heath A. B.; Barrowcliffe T. W. Variability in factor VIII concentrate measurement: results from SSC field collaborative studies. J Thromb Haemost: 2003; 1 9 1927 1934
35. Lee C. A.; Owens D.; Bray G.; et al. Pharmacokinetics of recombinant factor VIII (recombinate) using one-stage clotting and chromogenic factor VIII assay. Thromb Haemost: 1999; 82 6 1644 1647
36. Farrugia A. Potency assessment of the new generation of coagulation factor concentrates-time for a new paradigm? Thromb Haemost: 2003; 90 6 968 970
37. Christiansen M. L.; Balling K. W.; Persson E.; et al. Functional characteristics of N8, a new recombinant FVIII. Haemophilia: 2010; 16 6 878 887
38. White G.; Shapiro A.; Ragni M.; et al. Clinical evaluation of recombinant factor IX. Semin Hematol: 1998; 35 2 02 33 38
39. Ewenstein B. M.; Joist J. H.; Shapiro A. D.; et al. Mononine Comparison Study Group. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion: 2002; 42 2 190 197
40. Chevreux G.; Faid V.; Andre M. H.; Tellier Z.; Bihoreau N. Differential investigations from plasma-derived and recombinant Factor IX revealed major differences in post-translational modifications of activation peptides. Vox Sang: 2013; 104 2 171 174
41. Barrowcliffe T. W. Insights from factor IX activation studies with chromogenic assays: implications of disparate product results. Haemophilia: 2010; 16 06 9 12
42. Yu Y.; Millar C. M. Measurement of factor IX activity in plasma-derived and recombinant concentrates: insights from thrombin generation and activation-based assays. J Thromb Haemost: 2014; 12 1 62 70
43. Wilmot H. V.; Hogwood J.; Gray E. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays (epub ahead of print). Haemophilia: 2014
44. Kitchen S.; Gray E.; Mertens K. Monitoring of modified factor VIII and IX products. Haemophilia: 2014; 20 04 36 42
45. Hubbard A. R.; Dodt J.; Lee T.; et al. Factor VIII and Factor IX Subcommittee of The Scientific and Standardisation Committee of The International Society on Thrombosis and Haemostasis. Recommendations on the potency labelling of factor VIII and factor IX concentrates. J Thromb Haemost: 2013; 11 5 988 989
46. European Medicines Agency. Report of Workshop on Characterisation of New Clotting Factor Concentrates (FVIII, FIX) with Respect to Potency Assays Used for Labelling and Testing of Post Infusion Samples. 28-29 November 2013. Doc Ref. EMA/135928/2014. London, 26 June 2014. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Report/2014/07/WC500169760.pdf
47. Powell J. S.; Josephson N. C.; Quon D.; et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood: 2012; 119 13 3031 3037
48. Product information for Alprolix (Coagulation factor IX, recombinant, Fc fusion protein). Cambridge, MA: Biogen Idec Inc.
49. Sommer J. M.; Moore N.; McGuffie-Valentine B.; et al. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia: 2014; 20 2 294 300